Drug Profile
Ulixertinib - BioMed Valley Discoveries
Alternative Names: BVD-523; BVD-523FB; BVD-ERK; BVD-ERK/HM; BVD-ERK/ST; VRT-0752271; VRT-752271; VX-271Latest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Developer BioMed Valley Discoveries; Dana-Farber Cancer Institute; National Cancer Institute (USA)
- Class Amides; Aminopyridines; Antineoplastics; Chlorinated hydrocarbons; Pyrroles; Small molecules
- Mechanism of Action Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastrointestinal cancer; Non-Hodgkin's lymphoma; Solid tumours; Uveal melanoma
- Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
- Phase I Colorectal cancer; Glioma
- Phase Unknown Cancer
- No development reported Pancreatic cancer
Most Recent Events
- 21 Mar 2024 M.D. Anderson Cancer Center in collaboration with BioMed Valley Discoveries reinitiates a phase-I trial in Colorectal cancer (Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease, Combination therapy) in USA (PO) (NCT05985954)
- 07 Feb 2024 M.D. Anderson Cancer Center in collaboration with BioMed Valley Discoveries terminates a phase-I trial in Colorectal cancer (Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease, Combination therapy) in USA (PO) due to PI request (NCT05985954)
- 18 Jan 2024 Phase-I clinical trials in Colorectal cancer (Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease, Combination therapy) in USA (PO) (NCT05985954)